🚀 VC round data is live in beta, check it out!
Modus Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Modus Therapeutics and similar public comparables like Aton, Genxone, Instituto Rosenbusch, Akari Therapeutics and more.
Modus Therapeutics Overview
About Modus Therapeutics
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation, as well as states of anemia related to chronic inflammation, such as kidney diseases, through its patented polysaccharide, sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.
Founded
2011
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$4M
Modus Therapeutics Financials
Modus Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($2M).
In the same fiscal year, Modus Therapeutics generated ($2M) in EBITDA losses and had net loss of ($2M).
Modus Therapeutics P&L
In the most recent fiscal year, Modus Therapeutics reported revenue of — and EBITDA of ($2M).
Modus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Modus Therapeutics Stock Performance
Modus Therapeutics has current market cap of $6M, and enterprise value of $4M.
Market Cap Evolution
Modus Therapeutics' stock price is $0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $6M | 0.3% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialModus Therapeutics Valuation Multiples
Modus Therapeutics trades at (2.1x) EV/EBITDA.
Modus Therapeutics Financial Valuation Multiples
As of April 19, 2026, Modus Therapeutics has market cap of $6M and EV of $4M.
Equity research analysts estimate Modus Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Modus Therapeutics has a P/E ratio of (2.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (2.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Modus Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Modus Therapeutics Margins & Growth Rates
Modus Therapeutics' revenue in the last fiscal year grew by —.
Modus Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Modus Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Modus Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Modus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aton | XXX | XXX | XXX | XXX | XXX | XXX |
| Genxone | XXX | XXX | XXX | XXX | XXX | XXX |
| Instituto Rosenbusch | XXX | XXX | XXX | XXX | XXX | XXX |
| Akari Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Modus Therapeutics M&A Activity
Modus Therapeutics acquired XXX companies to date.
Last acquisition by Modus Therapeutics was on XXXXXXXX, XXXXX. Modus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Modus Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialModus Therapeutics Investment Activity
Modus Therapeutics invested in XXX companies to date.
Modus Therapeutics made its latest investment on XXXXXXXX, XXXXX. Modus Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Modus Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Modus Therapeutics
| When was Modus Therapeutics founded? | Modus Therapeutics was founded in 2011. |
| Where is Modus Therapeutics headquartered? | Modus Therapeutics is headquartered in Sweden. |
| How many employees does Modus Therapeutics have? | As of today, Modus Therapeutics has over 2 employees. |
| Is Modus Therapeutics publicly listed? | Yes, Modus Therapeutics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Modus Therapeutics? | Modus Therapeutics trades under MODTX ticker. |
| When did Modus Therapeutics go public? | Modus Therapeutics went public in 2021. |
| Who are competitors of Modus Therapeutics? | Modus Therapeutics main competitors are Aton, Genxone, Instituto Rosenbusch, Akari Therapeutics. |
| What is the current market cap of Modus Therapeutics? | Modus Therapeutics' current market cap is $6M. |
| Is Modus Therapeutics profitable? | No, Modus Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.